


LISTING OF CLAIMS

1-14 (canceled)

15. (currently amended) A compound selected from those of formula (I) :



5 wherein :

- R¹ represents an optionally substituted 5-membered heteroaryl group,
 - R² represents an optionally substituted cycloalkyl group,
 - R³ represents a hydrogen atom or an alkyl group, and
 - R⁴ and R⁵, which may be identical or different, each represents a hydrogen atom, a
- 10 halogen atom, or an alkyl group[[,]] or a polyhaloalkyl group, R¹⁰—C(X)—R¹¹—, R¹⁰—Y—C(X)—R¹¹—, R¹⁰—C(X)—Y—R¹¹—, R¹⁰—Y—R¹¹— or R¹⁰—S(O)_n—R¹¹—group,

in which:

- ~~R¹⁰ represents a hydrogen atom or an alkyl group,~~
- 15 ~~R¹¹ represents a bond, or an alkylene, alkenylene or alkynylene group,~~
- ~~X represents an oxygen atom, a sulphur atom, or an NR¹² group in which R¹² represents a hydrogen atom or an alkyl group,~~
- ~~Y represents an oxygen atom, a sulphur atom, or an amino or alkylamino group, and~~
- ~~n represents an integer of from 1 to 2 inclusive,~~

20 its enantiomers, diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base[[,]] .

it being understood that:

- the term "alkyl" denotes a linear or branched 1-6 carbon hydrocarbon chain;
- the term "alkoxy" denotes an alkyl-oxy group in which the 1-6 carbon alkyl chain, which may be linear or branched;
- the term "alkylene" denotes a linear or branched bivalent 1-6 carbon hydrocarbon chain;
- 5 - the term "alkenylene" denotes a linear or branched bivalent 1-6 carbon hydrocarbon chain with from 1 to 3 double bonds;
- the term "alkynylene" denotes a linear or branched bivalent 1-6 carbon hydrocarbon chain with from 1 to 3 triple bonds;
- the term "polyhaloalkyl" denotes a linear or branched 1-3 carbon and 1-7 halogen-carbon chain substituted by from 1 to 7 halogen atoms;
- 10 - the term "heteroaryl" denotes a mono- or bi-cyclic 5-11 ring-membered group which at least one of the rings is aromatic and optionally substituted in the monocycle or in the bicyclic 1, 2 or 3 hetero-atoms selected from nitrogen, oxygen and sulphur, and
- the term "cycloalkyl" denotes a 3-10 carbon hydrocarbon monocycle or bicyclic is optionally unsaturated by 1 or 2 unsaturated bonds;
- 15 - the expression "optionally substituted" associated with the terms cycloalkyl and heteroaryl denotes that the groups in question are unsubstituted or substituted by one or two identical or different substituents selected from halogen atoms and the groups alkyl, alkoxy, hydroxy, cyano, nitro, amino (optionally substituted by one or two alkyl groups) and C(O)R_d wherein R_d represents a group selected from hydroxy, alkoxy and amino, it being understood that the heteroaryl group may be additionally substituted by an oxo group on the non-aromatic moiety of the heteroaryl, unless otherwise noted.
- 20

16. (previously presented) A compound of claim 15 wherein R⁴ and R⁵, which may be identical or different, each represents a hydrogen atom or an alkyl group.

25 17. (previously presented) A compound of claim 15 wherein R³ represents a hydrogen atom.

18. (canceled)

19. (previously presented) A compound of claim 15 wherein R² represents a cyclopentyl, cyclohexyl or cycloheptyl group optionally substituted by an alkyl group.
- 5 20. (currently amended) A compound of claim 15 wherein R¹ represents an optionally substituted ~~5-to-6-membered~~ 5-membered heteroaryl group, R² represents a cyclohexyl or cycloheptyl group optionally substituted by an alkyl group, R³ represents a hydrogen atom and R⁴ and R⁵, which may be identical or different, each represents a hydrogen atom or an alkyl group.
21. (previously presented) A compound of claim 15 wherein the alkyl group is a methyl group.
- 10 22. (previously presented) A compound of claim 15 which is 2-[cyclohexyl(3-thienyl)methyl]-4-methyl-4,5-dihydro-1*H*-imidazole, its enantiomers, diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.
- 15 23. (previously presented) A compound of claim 15 which is (4*S*)-2-[cyclohexyl(3-thienyl)methyl]-4-methyl-4,5-dihydro-1*H*-imidazole, its diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.
- 20 24. (previously presented) A compound of claim 15 which is (4*R*)-2-[cyclohexyl(3-thienyl)methyl]-4-methyl-4,5-dihydro-1*H*-imidazole, its diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.
- 25 25. (previously presented) A pharmaceutical composition comprising as active principle an effective amount of a compound of claim 15 together with one or more pharmaceutically-acceptable excipients or vehicles.

26. (withdrawn) A method for treating a living animal body afflicted with a pathology associated with non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof, comprising the step of administering to the living animal body an amount of a compound of claim 15 which is effective for alleviation of the pathology.

27. (withdrawn) A method for treating a living animal body afflicted with a pathology associated with type I and type II diabetes and cardiovascular complications thereof, comprising the step of administering to the living animal body an amount of a compound of claim 15 which is effective for alleviation of the pathology.

28. (withdrawn) A method for treating a living animal body afflicted with pathology associated with type I and type II diabetes, comprising the step of administering to the living animal body an amount of a compound of claim 15 which is effective for alleviation of the pathology.